Premium
90 Y‐ibritumomab tiuxetan radiotherapy as first‐line therapy for early stage low‐grade B‐cell lymphomas, including bulky disease
Author(s) -
Samaniego Felipe,
Berkova Zuzana,
Romaguera Jorge E.,
Fowler Nathan,
Fanale Michelle A.,
Pro Barbara,
Shah Jatin J.,
McLaughlin Peter,
Sehgal Lalit,
Selvaraj Vijairam,
Braun Frank K.,
Mathur Rohit,
Feng Lei,
Neelapu Sattva S.,
Kwak Larry W.
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13021
Subject(s) - medicine , stage (stratigraphy) , marginal zone , gastroenterology , ibritumomab tiuxetan , lymphoma , marginal zone b cell lymphoma , follicular lymphoma , radiation therapy , progressive disease , b cell , chemotherapy , surgery , radioimmunotherapy , immunology , antibody , paleontology , monoclonal antibody , biology
Summary 90 Y‐ibritumomab‐tiuxetan ( 90 YIT ) was used as a first‐line therapy for patients with early‐stage follicular lymphoma ( FL ) or marginal zone B‐cell lymphoma ( MZL ). Thirty‐one patients were treated, with an overall 3‐month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow‐up of 56 months, ten patients (32%) had disease relapse or progression. The progression‐free rates at 3 and 5 years were lower in males, patients with FL , stage II diseaseand non‐bulky disease, although they did not reach statistical significance. Grade 3–4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. 90 YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early‐stage low‐grade B‐cell lymphomas. Bulky disease did not adversely affect tumour response.